These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6283566)

  • 21. Dynorphin A(1-13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393.
    Ukai M; Toyoshi T; Kameyama T
    Pharmacol Biochem Behav; 1992 Aug; 42(4):755-9. PubMed ID: 1355296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynorphin, an endogenous stimulator of feeding.
    Morley JE; Levine AS
    Prog Clin Biol Res; 1985; 192():293-300. PubMed ID: 2867550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynorphin A: inhibitory effect on other opiate ligand bindings in the mouse brain.
    Garzón J; Sánchez-Blázquez P; Gerhart J; Loh HH; Lee NM
    Biochem Pharmacol; 1984 Aug; 33(16):2609-14. PubMed ID: 6147144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of beta-chlornaltrexamine on food intake, body weight and opioid-induced feeding.
    Gosnell BA; Grace M; Levine AS
    Life Sci; 1987 Apr; 40(15):1459-67. PubMed ID: 2882401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine-opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression.
    Mavridis M; Besson MJ
    Neuroscience; 1999; 92(3):945-66. PubMed ID: 10426535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release.
    Mulder AH; Wardeh G; Hogenboom F; Frankhuyzen AL
    Nature; 1984 Mar 15-21; 308(5956):278-80. PubMed ID: 6322011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional studies with the opioid peptide dynorphin: acute effects of injections into the substantia nigra reticulata of naive rats.
    Herrera-Marschitz M; Hökfelt T; Ungerstedt U; Terenius L
    Life Sci; 1983; 33 Suppl 1():555-8. PubMed ID: 6141500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptidergic control of insulin-induced feeding.
    Levine AS; Morley JE
    Peptides; 1981; 2(3):261-4. PubMed ID: 7029493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynorphin inhibition of the neurotensin contractile activity on the myenteric plexus.
    Huidobro-Toro JP; Zhu YX; Lee NM; Loh HH; Way EL
    J Pharmacol Exp Ther; 1984 Feb; 228(2):293-303. PubMed ID: 6141281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naloxone reserves the inhibitory effects of dynorphin A on motor activity in the mouse.
    Ukai M; Yamada S; Kameyama T
    Pharmacol Biochem Behav; 1984 May; 20(5):815-8. PubMed ID: 6146145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The kappa opioid receptor and food intake.
    Morley JE; Levine AS; Kneip J; Grace M; Zeugner H; Shearman GT
    Eur J Pharmacol; 1985 May; 112(1):17-25. PubMed ID: 2990965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrophysiological effects of dynorphin peptides on hippocampal pyramidal cells in rat.
    Moises HC; Walker JM
    Eur J Pharmacol; 1985 Jan; 108(1):85-98. PubMed ID: 2858395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The choice of opioid receptor subtype in isolated preparations by dynorphins.
    Oka T; Aoki K; Kajiwara M
    Life Sci; 1983; 33 Suppl 1():311-4. PubMed ID: 6141492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of intranigral injections of dynorphin, dynorphin fragments and alpha-neoendorphin on rotational behaviour in the rat.
    Herrera-Marschitz M; Hökfelt T; Ungerstedt U; Terenius L; Goldstein M
    Eur J Pharmacol; 1984 Jul; 102(2):213-27. PubMed ID: 6148248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynorphin A (1-13), microinjected into the preoptic area, stimulates water intake in rats.
    Shimizu H; Shimomura Y; Negishi M; Kobayashi I; Kobayashi S
    Life Sci; 1989; 45(1):25-30. PubMed ID: 2568571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra.
    Quirion R; Gaudreau P; Martel JC; St-Pierre S; Zamir N
    Brain Res; 1985 Apr; 331(2):358-62. PubMed ID: 2859094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism.
    Levine AS; Morley JE
    Pharmacol Biochem Behav; 1982 Jun; 16(6):897-902. PubMed ID: 6125953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible modulatory role of dynorphin on the excitation by neurotensin on the guinea pig myenteric plexus.
    Huidobro-Toro JP; Way EL
    Neurosci Lett; 1982 Jun; 30(3):309-14. PubMed ID: 7110637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that dynorphin-(1-13) acts as an agonist on opioid kappa-receptors.
    Oka T; Negishi K; Suda M; Sawa A; Fujino M; Wakimasu M
    Eur J Pharmacol; 1982 Jan; 77(2-3):137-41. PubMed ID: 6277659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropeptides in spinal cord injury: comparative experimental models.
    Faden AI; Jacobs TP; Smith GP; Green B; Zivin JA
    Peptides; 1983; 4(5):631-4. PubMed ID: 6657511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.